← Leaderboards
Barry Jones
Arisaph Pharmaceuticals, Inc.
$1,059,889
Attributed
$2,119,778
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $695.6K · FY2011–15$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$2,119,778 · 4
By mechanism
R42$1,066,916 · 1
R41$1,052,862 · 3
Top collaborators
- William W Bachovchin7 shared
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseResistanceBaseKillingsSafetyChemotherapyTumorToxic EffectIn VivoDrug CandidateCancer PatientReportingOncogenesSmall Business Technology Transfer ResearchTumor GrowthCellsMutationNeoplastic CellMalignant NeoplasmsResponseClinical TrialsMouse ModelLeadInhibitor/Antagonist
Grant awards (7)
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$532,072
R42 · FY2015 · CA · contact PI
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$534,844
R42 · FY2014 · CA · contact PI
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma$160,721
R41 · FY2014 · CA · contact PI
A Small Molecule to Activate Tumor Immunity after PLX403 in V600E BRAF Melanoma$232,852
R41 · FY2013 · CA · contact PI
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors$147,010
R41 · FY2013 · CA · contact PI
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors$266,641
R41 · FY2012 · CA · contact PI
A FAP-Activated Proteasome Inhibitor for Killing Solid Tumors$245,638
R41 · FY2011 · CA · contact PI